TABLE 5.
Baseline expression of uPAR in treatment subgroups
| Group (no. of subjects)a | % | MLFI |
|---|---|---|
| Placebo, low (9) | 24 ± 21b | 115 ± 14 |
| Placebo, high (3) | 77 ± 16 | 590 ± 380 |
| COP-1, low (6) | 28 ± 23 | 113 ± 15 |
| COP-1, high (6) | 78 ± 31c | 582 ± 209c |
a
Patient groups were subdivided into those who began the study with baseline levels which were at control levels (MLFI, <300 [low]) and high levels (MLFI, ≥300 [high]).
b
Values are means ± SDs.
c
Statistically significantly different from the group with low baseline levels (P < 0.001).